ValiRx plc (GB:VAL) has released an update.
ValiRx PLC, a life science company specializing in cancer therapeutics and women’s health, has announced that its subsidiary, Inaphaea BioLabs Limited, has secured a revenue-bearing contract with a US-based biotech company. The contract involves a multi-stage project focusing on immuno-oncology, beginning with RNA data analysis and cell-based screening, and aims to foster a long-term relationship with potential for significant revenue. This agreement marks a strategic move for Inaphaea to expand its brand presence in the US biotech market.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
